# US 6,730,230 B2 · Use of high density microparticles for removal of pathogens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,230 B2
- Document ID: US6730230B2
- Status: Granted
- Kind: B2
- Application number: 10/043,471
- Filed: 2002-01-11
- Published: 2002-08-29
- Granted: 2004-05-04
- Earliest claimed: 2001-01-16
- Assignees: Miltenyi Biotec GmbH
- Inventors: David N. Cook; Rodney L. Monroy
- Web page: https://patentgrep.com/patent/US6730230B2

## CPC

- G01N 33/54313: {the carrier being characterised by its particulate form}
- G01N 33/569: for microorganisms, e.g. protozoa, bacteria, viruses
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods of using high-density microparticles to bind and remove pathogens from biological fluids are disclosed. Pathogens include prions, viruses, bacteria and protozoa.

## Claims

### Claim 1

A method of removing at least one population of target pathogens from a biological fluid sample, comprising:
(a) providing a plurality of high density microparticles having bound thereto a reactant which specifically binds to the target pathogen, and having a density sufficient to provide differential gravity settling of the target pathogen from the sample;
(b) mixing a portion of the sample with the microparticles to bind the microparticles to the target pathogen;
(c) settling the microparticles with the bound pathogen in the sample to produce a supernatant substantially free from the bound pathogen, where the settling is accomplished primarily by gravity; and
(d) separating the microparticles bound to the pathogen from the supernatant.

### Claim 2 (depends on 1)

The method of claim 1 wherein said mixing is effected by passing the microparticles at least once through the sample.

### Claim 3 (depends on 2)

The method of claim 2 wherein said mixing and settling steps are conducted simultaneously such that mixing is effected solely by differential gravity settling.

### Claim 4 (depends on 2)

The method of claim 2 wherein said mixing is effected by causing the microparticles to repeatedly settle through a substantial portion of the sample.

### Claim 5 (depends on 4)

The method of claim 4 wherein said mixing is effected by vortexing or nutation.

### Claim 6 (depends on 4)

The method of claim 4 wherein said mixing is effected by tumbling the sample and the microparticles end-over-end.

### Claim 7 (depends on 1)

The method of claim 1 which further comprises spinning the microparticles and sample to accelerate the settling step.

### Claim 8 (depends on 1)

The method of claim 1, wherein said microparticles are magnetic and said method further comprises applying a magnet or magnetic field to the sample and microparticles after the settling step.

### Claim 9 (depends on 1)

The method of claim 1 wherein more than one population of pathogens are removed sequentially or all at one time.

### Claim 10 (depends on 1)

The method of claim 1 wherein the reactant is an antibody.

### Claim 11 (depends on 1)

The method of claim 1 wherein the reactant is bound covalently to the microparticles.

### Claim 12 (depends on 1)

The method of claim 1 wherein the reactant is bound to the microparticles by streptavidin-biotin coupling.

### Claim 13 (depends on 1)

The method of claim 1 wherein said microparticles are formed of nickel.

### Claim 14 (depends on 1)

The method of claim 1 wherein said microparticles have a diameter of 1 to 50 microns.

### Claim 15 (depends on 1)

The method of claim 1 wherein said microparticles have a diameter of 3 to 35 microns.

### Claim 16 (depends on 1)

The method of claim 1 wherein said biological fluid sample comprises non-target materials and the microparticles are 2 to 3 times more dense than said non-target materials.

### Claim 17 (depends on 15)

The method of claim 15 wherein said microparticles have a density greater than 2 g/cm3.

### Claim 18 (depends on 16)

The method of claim 16 wherein said microparticles have a density of 9 gm/cm3.

### Claim 19 (depends on 1)

The method of claim 1 wherein the biological fluid sample is dispersed tissue, bone marrow aspirates or vertebral body bone marrow.

### Claim 20 (depends on 18)

The method of claim 18 wherein the supematant is used for clinical transplantation.

### Claim 21 (depends on 1)

The method of claim 1 wherein the volume of the fluid sample ranges from 100 milliliters to 3 liters.

### Claim 22 (depends on 1)

The method of claim 1 wherein the target pathogen is a prion.

### Claim 23 (depends on 1)

The method of claim 1 wherein the target pathogen is a virus.

### Claim 24 (depends on 1)

The method of claim 1 wherein the target pathogen is a bacterium.

### Claim 25 (depends on 24)

The method of claim 24 wherein the bacterium is Bacillus anthracis.

### Claim 26 (depends on 24)

The method of claim 24 wherein the bacterium is Yersinia pestis.

### Claim 27 (depends on 24)

The method of claim 24 wherein the bacterium is Francisella tularensis.

### Claim 28 (depends on 1)

The method of claim 1 wherein said microparticles are coated with a poly (glutamic acid, lysine, tyrosine) tri-amino acid polymer, wherein said glutamic acid, said lysine, and said tyrosine are present in said tri-amino acid polymer at a ratio of glutamic acid to lysine to tyrosine of 6:3:1.
